Medicaid programs have implemented a variety of policies aiming to control drug cost. One of the Medicaid state programs use different criteria to set the reimbursement for brand and generic drugs.
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This study assessed trends in state-level, fee-for-service Medicaid generic and brand drug utilization and expenditures, and pharmacy reimbursement rates in the period 2010-2012.
Pharmacy expenditures decreased in the period 2010-2012 due to a decrease in the volume of prescriptions and the reduction in generic prices.
Differences in dispensing fees and ingredient costs among Medicaid programs were independent of total prescription volume.
Future studies could evaluate dispensing patterns of brand drugs when generic alternatives are available, and potential saving from increasing the utilization of generic drugs. The average pharmacy dispensing fee increased from $4.34±$1.24 to $4.60±$2.56 for generics and from $4.10±$1.19 to $4.38±$2.58 for brands. We found no statistically significant relationship between the number of claims or the total state expenditures, and the dispensing fee or the average ingredient cost. We found a significant variation in generic utilization across states in the period 2010-2012. On average 75% of all prescription paid by Medicaid were generics.
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Nearly 50% of the states had generic utilization rates below the national average (75%).
These findings suggest that additional savings could be achieved by promoting generic drug utilization in Medicaid programs, especially in states with low generic utilization rates. 
